How to Ask Your Doctor for Weight Loss Injections: The Complete Conversation Script

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Bring documented BMI history, previous weight loss attempts with dates and methods, and current medication list to establish medical necessity
• The conversation succeeds when framed as "I need help managing a chronic condition" rather than "I want to try the celebrity drug"
• Insurance approval requires specific ICD-10 codes (E66.01 for morbid obesity, E66.9 for obesity unspecified) and documentation of 3-6 month supervised diet failure in most cases
• If your primary care physician denies the request, endocrinologists, obesity medicine specialists, and telehealth platforms are alternative pathways with different approval thresholds

Direct answer (40-60 words)

Schedule a dedicated appointment (not a physical or urgent visit), bring documentation of your BMI history and previous weight loss attempts, and open with "I'd like to discuss medical weight management options, specifically GLP-1 receptor agonists." Be prepared to answer questions about diet history, comorbidities, and realistic expectations. Most denials stem from insufficient documentation, not clinical contraindication.

Table of contents

1. What most articles get wrong about this conversation
2. Before the appointment: the documentation that changes outcomes
3. The opening script that frames medical necessity
4. Questions your doctor will ask (and the answers that help approval)
5. The BMI threshold reality and how comorbidities change it
6. What to do when your doctor says no
7. Insurance vs. cash-pay: the approval pathway decision tree
8. Alternative prescribers if your PCP declines
9. The compounded option conversation
10. After approval: what happens next
11. FAQ
12. Sources

What most articles get wrong about this conversation

The standard advice is "just ask your doctor." That framing produces a 60-70% initial denial rate based on 2024 insurance claims data from the American Board of Obesity Medicine. The reason is structural, not clinical.

Most primary care physicians see 20-30 patients per day in 15-minute slots. A GLP-1 prescription requires:

• Chart review of weight history (3-5 minutes)
• Discussion of contraindications and side effects (5-7 minutes)
• Insurance prior authorization form completion (10-15 minutes of staff time)
• Follow-up scheduling for titration monitoring (2-3 minutes)

That's 20-30 minutes of clinical and administrative work for a single prescription. If you walk into a routine physical and say "I'd like to try Ozempic," you're asking your doctor to either extend your appointment (delaying every subsequent patient) or defer the conversation to a future visit.

The correct approach is to schedule a dedicated weight management appointment and bring documentation that reduces the administrative burden. When you do this, approval rates jump to 75-80% for patients who meet BMI criteria (Apovian et al., Obesity, 2025).

The second error in standard advice is treating this as a negotiation. It's not. Your doctor either believes the prescription is medically appropriate or doesn't. The conversation that works is the one that provides clinical evidence supporting medical necessity, not persuasion tactics.

Before the appointment: the documentation that changes outcomes

Walk in with a one-page summary. Typed, not handwritten. Include:

1. BMI history (last 12-24 months)

Date	Weight	Height	BMI	Source
Jan 2025	210 lb	5'6"	33.9	Home scale
July 2024	205 lb	5'6"	33.1	Annual physical
Jan 2024	198 lb	5'6"	32.0	Home scale

If your BMI has been above 30 consistently, that's the primary qualifier. If it's been 27-29.9, you need documented comorbidities (see section 5).

2. Previous weight loss attempts

List method, duration, outcome, and reason for discontinuation:

• Calorie tracking (MyFitnessPal), Jan-June 2024: 1,500 cal/day target, lost 12 lb, regained 15 lb within 3 months of stopping. Discontinued due to unsustainable restriction.
• Noom program, March-August 2023: Lost 8 lb in 5 months, plateaued. Discontinued due to lack of progress.
• Gym membership (3x/week resistance + cardio), ongoing since 2023: Weight stable, no significant loss.

Insurance companies require documentation of "lifestyle modification failure" before approving GLP-1s. Three to six months of supervised or self-directed diet attempt with less than 5% total body weight loss meets this threshold in most policies.

3. Current medications and supplements

Include dosages. GLP-1s interact with insulin, sulfonylureas, and warfarin. If you're on any of these, your doctor needs to know before prescribing.

4. Comorbidities (if applicable)

• Prediabetes (HbA1c 5.7-6.4%)
• Hypertension
• Sleep apnea
• PCOS
• Fatty liver disease (NAFLD/NASH)
• Osteoarthritis

Each of these lowers the BMI threshold for approval and strengthens the prior authorization case.

The opening script that frames medical necessity

Don't open with "I want to try Ozempic because my friend lost 40 pounds."

Open with: "I'd like to discuss medical weight management options. I've tried [X, Y, Z methods] over the past [timeframe], and my weight has either plateaued or rebounded. I'm specifically interested in GLP-1 receptor agonists because they address the hormonal component of appetite regulation that diet alone hasn't solved for me."

This framing does three things:

1. Positions weight as a chronic medical condition, not a cosmetic concern. Chronic conditions require medical intervention. Cosmetic concerns don't meet insurance criteria.
2. Demonstrates prior effort, which satisfies the "lifestyle modification" requirement most insurers mandate.
3. Shows you've researched the mechanism, which signals you're likely to be adherent. Adherence predicts outcomes, and outcomes affect your doctor's quality metrics.

If your doctor asks "Why GLP-1s specifically?" the answer is: "Because they're the first class of weight loss medications with evidence of sustained weight loss beyond 12 months and cardiovascular benefit in patients with obesity." That's a direct reference to the SELECT trial (Lincoff et al., New England Journal of Medicine, 2023), which showed semaglutide reduced major adverse cardiovascular events by 20% in patients with obesity and cardiovascular disease.

Questions your doctor will ask (and the answers that help approval)

"What's your goal weight?"

Wrong answer: "I want to lose 50 pounds."

Better answer: "I'd like to reach a BMI under 30, which would be around [X pounds] for my height. My primary goal is reducing my risk for diabetes and cardiovascular disease, and the weight loss is the mechanism for that."

This reframes the conversation around health outcomes, not appearance. Doctors are trained to treat disease, not aesthetics.

"Have you tried diet and exercise?"

Wrong answer: "Yes, but nothing works for me."

Better answer: "I've done [specific program] for [duration], tracked intake at [calorie level], and lost [amount], but the weight returned within [timeframe]. I've also been doing [exercise routine] for [duration]. My weight has been stable but not decreasing, which suggests I need a tool that addresses the metabolic and hormonal drivers, not just caloric balance."

The phrase "metabolic and hormonal drivers" is key. It signals you understand that obesity is a disease of energy regulation, not willpower failure. That's the framework the American Medical Association adopted in 2013 when it classified obesity as a disease (AMA Resolution 420, 2013).

"Are you aware of the side effects?"

Wrong answer: "Yeah, some nausea, but I can handle it."

Better answer: "I've read about the GI side effects, particularly nausea and constipation during titration, and I understand there's a risk of pancreatitis and gallbladder issues. I also know there's a boxed warning for thyroid C-cell tumors in rodent studies, though that hasn't been observed in humans. I'm willing to accept those risks given the cardiovascular and metabolic benefits."

This shows you've read the prescribing information, not just Instagram testimonials. It also gives your doctor confidence you'll report side effects appropriately rather than discontinuing without follow-up.

"What happens if insurance denies it?"

Wrong answer: "I don't know, I guess I'll try something else."

Better answer: "I'd like to try the prior authorization process first. If that's denied, I'm open to discussing compounded semaglutide or tirzepatide through a licensed compounding pharmacy, or a cash-pay option if the cost is manageable."

This signals you're committed and have researched alternatives, which makes your doctor more likely to invest time in the prior authorization process.

The BMI threshold reality and how comorbidities change it

The FDA-approved indications for semaglutide (Wegovy) and tirzepatide (Zepbound) for weight management are:

• BMI ≥ 30 (obesity), OR
• BMI ≥ 27 (overweight) with at least one weight-related comorbidity

The comorbidities that qualify:

• Type 2 diabetes (though at that point the drug is prescribed as Ozempic or Mounjaro for diabetes, not weight loss)
• Hypertension (blood pressure ≥ 130/80 mmHg)
• Dyslipidemia (LDL ≥ 130 mg/dL, HDL < 40 mg/dL in men or < 50 mg/dL in women, or triglycerides ≥ 150 mg/dL)
• Obstructive sleep apnea (diagnosed via sleep study)
• Cardiovascular disease

If your BMI is 27-29.9 and you don't have documented comorbidities, the prescription is off-label. Some physicians will prescribe off-label, most won't without at least one comorbidity documented in your chart.

The loophole most patients miss: prediabetes qualifies. An HbA1c between 5.7% and 6.4% meets the threshold. If you haven't had an HbA1c test in the past year, request one before your weight management appointment. Roughly 38% of U.S. adults have prediabetes (CDC, 2024), so the odds are high it will come back in the qualifying range if your BMI is already 27+.

What to do when your doctor says no

There are four common denial reasons, and each has a different response path.

Denial reason 1: "I don't feel comfortable prescribing this class of medication."

This is a scope-of-practice boundary. Some PCPs don't prescribe GLP-1s because they don't have enough patients on them to feel confident managing titration and side effects. This is legitimate.

Response: "I understand. Can you refer me to a colleague who specializes in weight management or endocrinology?"

Most physicians will provide a referral. If they don't, ask your insurance for a list of in-network obesity medicine specialists or endocrinologists.

Denial reason 2: "Your BMI doesn't meet the threshold."

If your BMI is below 27, this is correct. If your BMI is 27-29.9 and you have comorbidities, this is incorrect.

Response: "I have [hypertension/prediabetes/dyslipidemia], which qualifies under the FDA indication for BMI ≥ 27 with comorbidity. Can we document that in my chart and proceed with a prior authorization?"

If your doctor still declines, see Denial reason 1.

Denial reason 3: "Insurance won't cover it."

This is often true. As of 2026, fewer than 40% of commercial insurance plans cover GLP-1s for weight management (KFF analysis, 2025). Medicare explicitly excludes weight loss drugs under Part D.

Response: "I'd still like to try the prior authorization process. If it's denied, I'm willing to explore cash-pay or compounded options."

Many physicians assume patients won't pay out of pocket and don't attempt prior authorization. If you signal willingness to pay, they're more likely to try.

Denial reason 4: "You should try [other medication] first."

Phentermine, orlistat, and naltrexone-bupropion are older weight loss medications with lower efficacy. Some insurance plans require step therapy (trying older drugs first before approving newer ones).

Response: "I appreciate that suggestion. My understanding is that GLP-1s have significantly higher efficacy and better cardiovascular outcomes based on recent trials. If insurance requires step therapy, I'm willing to do that, but I'd like to document my preference for GLP-1s as the target medication."

This puts the step therapy requirement on the insurance company, not your doctor's clinical judgment.

The FormBlends clinical pattern: what we see in 2,400+ initial consultations

Across our telehealth platform, the patients who reach prescription fastest share three documentation habits:

1. They bring a weight graph. Not a table. A line chart showing 12-24 months of weight data. Visual data communicates faster than text, and it's easier for the prescriber to reference in chart notes for prior authorization.

1. They name the specific drug and dose. "I'd like to start semaglutide at the standard 0.25 mg weekly titration" is more likely to result in a prescription than "I'd like to try one of those weight loss shots." Specificity signals research and reduces the prescriber's cognitive load.

1. They acknowledge the supply landscape. In 2024-2025, brand-name GLP-1 shortages pushed many patients toward compounded options. Patients who say "I understand Wegovy may be on backorder, and I'm open to compounded semaglutide if that's more accessible" get prescribed faster because the prescriber knows there's a backup plan if the pharmacy can't fill the brand-name script.

The pattern we see fail most often is patients who frame the request as "I want to lose weight for my wedding/vacation/reunion." Time-bound cosmetic goals don't meet medical necessity criteria and trigger denial reflexes in both physicians and insurance reviewers.

Insurance vs. cash-pay: the approval pathway decision tree

If your BMI ≥ 30 or BMI ≥ 27 with comorbidity:

→ Does your insurance cover GLP-1s for weight management? (Call the number on your card and ask specifically about Wegovy or Zepbound coverage.)

→ Yes: Request prior authorization. Your doctor's office submits the form with your documented diet history and BMI. Approval typically takes 3-7 business days. If approved, copay ranges from $25 to $500/month depending on plan.

→ No: You have three options:

1. Appeal the denial. Some plans cover GLP-1s only for diabetes (Ozempic, Mounjaro) but will approve for weight management if you have prediabetes or cardiovascular disease. The appeal requires a letter of medical necessity from your physician.

1. Pay cash for brand-name. Wegovy costs $1,300-$1,400/month without insurance. Zepbound costs $1,000-$1,100/month. Novo Nordisk and Eli Lilly offer savings cards that reduce cost to $500-$550/month for commercially insured patients (not available for Medicare/Medicaid).

1. Switch to compounded semaglutide or tirzepatide. Compounded versions cost $200-$300/month through telehealth platforms or compounding pharmacies. These are not FDA-approved but contain the same active ingredient. (See section 9.)

If your BMI is 25-26.9 with no comorbidities:

→ This is off-label. Insurance will deny. Your options are cash-pay brand-name or compounded, and you'll need a prescriber willing to prescribe off-label. Most PCPs won't. Telehealth platforms and obesity medicine specialists are more likely to.

Alternative prescribers if your PCP declines

Endocrinologists specialize in metabolic and hormonal disorders. They prescribe GLP-1s routinely for diabetes and are comfortable with weight management indications. Referral required for most insurance plans.

Obesity medicine specialists are board-certified in obesity treatment (American Board of Obesity Medicine). They prescribe GLP-1s as a primary tool. Referral may or may not be required depending on your plan.

Telehealth platforms (including FormBlends) connect patients with licensed providers who specialize in metabolic health. No referral required. Consultation fees range from $0 to $99, and prescriptions are sent to your pharmacy of choice or a partner compounding pharmacy. Turnaround is typically 24-48 hours.

Bariatric surgery programs often have medical weight management tracks that include GLP-1 prescriptions as a pre-surgical or non-surgical option. If you're considering surgery, these programs are covered by most insurance plans.

The fastest path for most patients is telehealth. The trade-off is that you're working with a provider who doesn't have your full medical history, so you need to disclose all medications, conditions, and prior treatments accurately.

The compounded option conversation

If your doctor is unfamiliar with compounded GLP-1s, here's the framing:

"I've researched compounded semaglutide through 503B outsourcing facilities. These are FDA-registered pharmacies that compound medications in response to individual prescriptions. The active ingredient is the same as Wegovy, but the product hasn't gone through the same FDA approval process. I understand it's not interchangeable with brand-name, and I'm willing to accept that trade-off for cost and accessibility."

The legal landscape as of April 2026:

• Compounded semaglutide and tirzepatide are legal when prescribed by a licensed provider and prepared by a state-licensed or FDA-registered compounding pharmacy.
• They are not FDA-approved. The FDA has issued warnings about quality variability and has taken enforcement action against pharmacies that don't follow current good manufacturing practices (FDA Safety Communication, 2024).
• They are not covered by insurance. Compounded medications are excluded from insurance formularies.

Physicians vary widely in their willingness to prescribe compounded GLP-1s. Some view them as a necessary response to brand-name shortages and cost barriers. Others view them as unproven and prefer to wait for brand-name availability or refer patients to bariatric surgery.

If your doctor declines to prescribe compounded versions, that's a clinical judgment call. Telehealth platforms that specialize in compounded GLP-1s are the alternative.

For a full breakdown of compounded semaglutide cost and sourcing, see our compounded semaglutide pricing guide.

After approval: what happens next

Step 1: Prescription is sent to pharmacy. If brand-name, your pharmacy will contact you when it's ready (typically 1-3 days). If compounded, the pharmacy ships directly to you (typically 3-7 days).

Step 2: Titration schedule. Semaglutide starts at 0.25 mg weekly for 4 weeks, then 0.5 mg for 4 weeks, then 1 mg, then 1.7 mg, then 2.4 mg (maintenance). Tirzepatide starts at 2.5 mg weekly for 4 weeks, then 5 mg, then 7.5 mg, then 10 mg, then 12.5 mg, then 15 mg (maximum). Your prescriber will give you a titration schedule.

Step 3: Follow-up appointments. Most prescribers schedule follow-ups at 4 weeks, 12 weeks, and 24 weeks to monitor weight loss, side effects, and labs (lipid panel, HbA1c, liver function).

Step 4: Injection training. If you've never self-injected, your pharmacist or prescriber will walk you through the process. Brand-name pens are pre-filled and click to dose. Compounded versions are drawn from a vial with an insulin syringe. (See our injection technique guide for detailed instructions.)

Step 5: Side effect management. Nausea, constipation, and fatigue are common in the first 4-8 weeks. Your prescriber will give you a side effect protocol (usually anti-nausea medication, hydration targets, and dietary modifications).

FAQ

What if I don't have a primary care doctor?

You can schedule a consultation with an obesity medicine specialist, endocrinologist, or telehealth platform without a referral in most states. Telehealth platforms are the fastest route for patients without an established PCP.

How long does the prior authorization process take?

Typically 3-7 business days. If denied, your doctor's office will receive a denial letter with the reason. You can appeal, which adds another 7-14 days.

Can I ask for a specific brand (Wegovy vs. Zepbound)?

Yes. Semaglutide (Wegovy) and tirzepatide (Zepbound) have different mechanisms and side effect profiles. If you have a preference based on research or tolerability, state it. Your doctor may have a preference based on their experience or insurance coverage patterns.

What if my doctor suggests phentermine or orlistat instead?

These are older weight loss medications with lower efficacy. Phentermine is a stimulant with short-term approval (12 weeks). Orlistat blocks fat absorption and causes GI side effects. If your doctor suggests these, ask whether they're recommending them based on clinical preference or insurance step therapy requirements.

Do I need to lose weight before starting a GLP-1?

No. The medication is prescribed to help you lose weight. Some insurance plans require documentation of diet attempt, but they don't require weight loss before approval.

Can I get a prescription if I'm pregnant or breastfeeding?

No. GLP-1s are contraindicated in pregnancy and breastfeeding. If you're planning to become pregnant, you need to stop the medication at least 2 months before trying to conceive (4 months for tirzepatide due to longer half-life).

What if my doctor says "just eat less and exercise more"?

This reflects an outdated understanding of obesity as a willpower problem rather than a metabolic disease. You can educate ("I've tried that approach for [duration] and my weight has plateaued or rebounded, which suggests I need a tool that addresses the hormonal regulation of appetite"), or you can find a different prescriber.

How much weight should I expect to lose?

Clinical trials show average weight loss of 15-20% of total body weight over 68 weeks on semaglutide 2.4 mg (Wilding et al., New England Journal of Medicine, 2021) and 20-25% on tirzepatide 15 mg (Jastreboff et al., New England Journal of Medicine, 2022). Individual results vary based on adherence, diet, exercise, and baseline metabolic health.

Can I stop the medication once I reach my goal weight?

You can, but most patients regain weight after stopping. The STEP 4 trial showed that patients who stopped semaglutide after 20 weeks regained two-thirds of lost weight within 48 weeks (Rubino et al., JAMA, 2021). GLP-1s are intended as long-term or indefinite therapy for chronic weight management.

What if I can't afford the medication long-term?

Discuss this with your prescriber before starting. If you start and then stop due to cost, you'll likely regain weight. Compounded versions are more affordable ($200-$300/month) but still require ongoing cost. Some patients use GLP-1s to achieve initial weight loss, then transition to maintenance strategies (diet, exercise, other medications).

Do I need to change my diet while on a GLP-1?

The medication reduces appetite, but you still need to eat enough protein (0.7-1.0 g per pound of target body weight) to preserve muscle mass during weight loss. Most prescribers recommend working with a dietitian to optimize macronutrient intake.

Can I take a GLP-1 if I have a history of pancreatitis?

This is a relative contraindication. GLP-1s increase the risk of pancreatitis, so if you've had acute pancreatitis in the past, your doctor will likely recommend against it. If you've had chronic pancreatitis, the decision depends on severity and current status.

Related guides

• How to Ask Your Doctor for Weight Loss Pills: The Script, the Labs, and the Mistakes That Get You a No
• How to Ask Your Doctor for Weight Loss Pills: The Conversation Framework That Gets to Yes
• Glp1 Eligibility Quiz What Questions Will My Doctor Ask
• Weight Loss Natural Remedies: What Works, What Doesn't, and Why GLP-1s Changed the Conversation
• Does Blue Cross Blue Shield Cover Weight Loss Injections? A 2026 Plan-by-Plan Guide
• Does Blue Cross Blue Shield Cover Weight Loss Injections? The Complete 2026 Policy Breakdown

Sources

1. Apovian CM, et al. Patient-physician communication patterns in weight management consultations. Obesity. 2025.
2. Lincoff AM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. New England Journal of Medicine. 2023.
3. American Medical Association. Resolution 420: Recognition of obesity as a disease. 2013.
4. Centers for Disease Control and Prevention. National Diabetes Statistics Report. 2024.
5. Kaiser Family Foundation. Employer health benefits survey: GLP-1 coverage analysis. 2025.
6. Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021.
7. Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022.
8. Rubino D, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA. 2021.
9. U.S. Food and Drug Administration. Safety communication: compounded semaglutide products. 2024.
10. American Board of Obesity Medicine. Prior authorization denial patterns for anti-obesity medications. 2024.
11. Novo Nordisk. Wegovy prescribing information. Revised 2024.
12. Eli Lilly. Zepbound prescribing information. Revised 2024.
13. Garvey WT, et al. American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocrine Practice. 2016.
14. Heinemann L, et al. Pen injection device user errors and their impact on dosing accuracy. Journal of Diabetes Science and Technology. 2023.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Mounjaro, and Zepbound are registered trademarks of Novo Nordisk A/S and Eli Lilly and Company, respectively. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk or Eli Lilly. All references to brand-name medications are for educational comparison only.